Decentralized scientific trial firm Curebase is partnering with Meru Well being on a three-year scientific trial to review the effectiveness of Meru’s 12-week therapy program aimed toward decreasing melancholy amongst main care sufferers.
Meru Well being’s smartphone-based, therapist-guided therapy program targets melancholy, burnout and nervousness, whereas Curebase supplies a decentralized scientific trial platform connecting researchers with trial contributors, streamlining the paperwork and permitting for distant examine administration.
The 2-phase trial will start with a proof-of-concept part, the place 15 sufferers will use Meru Well being’s therapy program. One other 15 will bear conventional therapy strategies, corresponding to face-to-face remedy, antidepressants or mixture remedy, below the supervision of their main care doctor.
As soon as the proof-of-concept part concludes, the 2 corporations will collaborate for a randomized managed trial (RCT), which is able to embody 300 contributors and eight main care clinics throughout the U.S.
Through the RCT, Curebase and Meru Well being will gather digital patient-reported outcomes for evaluation. After contributors full the therapy program, researchers will monitor their progress for as much as a 12 months to judge the sustained results of the Meru’s therapy program in comparison with commonplace therapy strategies.
The trial was funded by the Nationwide Institutes of Well being’s Small Enterprise Innovation Analysis program and is slated to start recruitment in autumn 2022. It is anticipated to conclude by spring 2023.
“Too many people who find themselves battling psychological well being points additionally wrestle with having access to efficient therapy and our resolution was created to assist these individuals,” Kristian Ranta, founder and CEO of Meru Well being, mentioned in a press release. “Curebase is a perfect associate for us as a result of the corporate’s DCT platform and assist providers permit us to concentrate on the scientific points of those trials, whereas treating taking part sufferers at quite a lot of places.”
THE LARGER TREND
Numerous digital well being corporations supply know-how for conducting decentralized scientific trials, together with Medable, Reify Well being and THREAD. Curebase lately closed a $40 million Collection B funding spherical, bringing its whole elevate to $59 million.
Digital psychological well being continues to be a well-liked scientific space for funding, at the same time as total digital well being funding has declined up to now in 2022. Meru raised $38 million in Collection B fairness and debt funding final 12 months, following an $8.1 million Collection A in 2020.
“Meru Well being’s smartphone-based psychological well being program reveals great potential for bringing efficient and accessible therapy to the rising inhabitants of melancholy and nervousness sufferers,” Curebase CEO and founder Tom Lemberg mentioned in a press release. “We’re excited to be working with Meru Well being on scientific analysis that has the potential to learn tens of millions of Individuals.”